Expertise in
7
conditions

Dr. Onyema Ogbuagu

Infectious Disease
Yale New Haven Hospital
20 York St, 
New Haven, CT 
Expertise in
7
conditions
Yale New Haven Hospital
20 York St, 
New Haven, CT 

Overview

Onyema Ogbuagu is an Infectious Disease provider in New Haven, Connecticut. Dr. Ogbuagu is highly rated in 7 conditions, according to our data. His top areas of expertise are HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, AIDS Dementia Complex, and Endoscopy.

His clinical research consists of co-authoring 80 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Infectious Disease

Licenses

Internal Medicine in CT

Hospital Affiliations

Yale-New Haven Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

Yale New Haven Hospital
20 York St, New Haven, CT 06510

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)
A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drug: Leronlimab
Study Phase: Phase 2
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Current antiretroviral regimen
Study Phase: Phase 3
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)
Enrollment Status: Completed
Publish Date: January 04, 2023
Intervention Type: Drug
Study Drug: Leronlimab
Study Phase: Phase 2
A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
Enrollment Status: Withdrawn
Publish Date: September 20, 2021
Intervention Type: Drug
Study Phase: Phase 4
View 4 Less Clinical Trials

80 Total Publications

Lenacapavir treatment-emergent HIV-1 capsid resistance mutations are frequently associated with replication defects.
Lenacapavir treatment-emergent HIV-1 capsid resistance mutations are frequently associated with replication defects.
Journal: Science translational medicine
Published: January 07, 2026
Similar Doctors
Expertise in
3
conditions
Dr. Michael Cappello
Infectious Disease
Expertise in
3
conditions
Dr. Michael Cappello
Infectious Disease

Yale New Haven Childrens Hospital

1 Park St, 
New Haven, CT 
 (0.1 miles away)
203-785-4730
Languages Spoken:
English
See accepted insurances

Michael Cappello is an Infectious Disease provider in New Haven, Connecticut. Dr. Cappello is highly rated in 3 conditions, according to our data. His top areas of expertise are Hookworm Infection, Secernentea Infections, Helminthiasis, and Malaria.

Expertise in
2
conditions
Dr. Manisha Juthani
Infectious Disease
Expertise in
2
conditions
Dr. Manisha Juthani
Infectious Disease

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (0.1 miles away)
203-785-2140
Languages Spoken:
English
See accepted insurances

Manisha Juthani is an Infectious Disease provider in New Haven, Connecticut. Dr. Juthani is highly rated in 2 conditions, according to our data. Her top areas of expertise are Asymptomatic Bacteriuria, Pneumonia, and Hospital-Acquired Pneumonia.

Expertise in
9
conditions
Dr. Gary Wormser
Infectious Disease
Expertise in
9
conditions
Dr. Gary Wormser
Infectious Disease

Cardiology Consultants

19 Bradhurst Ave, 
Hawthorne, NY 
 (47.4 miles away)
914-493-8865
Languages Spoken:
English
See accepted insurances

Gary Wormser is an Infectious Disease provider in Hawthorne, New York. Dr. Wormser is highly rated in 9 conditions, according to our data. His top areas of expertise are Lyme Disease, Babesiosis, Human Granulocytic Ehrlichiosis, Ehrlichiosis, and Splenectomy.

Frequently Asked Questions about Dr. Onyema Ogbuagu

How do I make an appointment with Dr. Onyema Ogbuagu?

You can book an appointment with Dr. Onyema Ogbuagu by calling their office at 203-688-6959. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Onyema Ogbuagu a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Onyema Ogbuagu is classified as an Distinguished expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Onyema Ogbuagu specialize in?

While Dr. Onyema Ogbuagu is a Infectious Disease, they have specific expertise in HIV/AIDS, Myelitis, and AIDS Dysmorphic Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.

Does Dr. Onyema Ogbuagu participate in research or clinical trials?

Yes. Dr. Onyema Ogbuagu has published 80 articles and abstracts on conditions like HIV/AIDS. You can view a list of Dr. Onyema Ogbuagu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Onyema Ogbuagu accept my insurance?

Dr. Onyema Ogbuagu accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 203-688-6959 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ogbuagu's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile